Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD

ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
October 27, 2025 09:22 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
October 20, 2025 07:41 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
October 14, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 08, 2025 07:09 ET | Source: Nilo Therapeutics

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Nilo Therapeutics launches with $101 million Series A to target neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
October 07, 2025 10:30 ET | Source: Precedence Research

Digital Therapeutics Market Size to Lead USD 56.76 Bn by 2034 Driven by Digital Therapeutics, Cost Control, and Chronic Disease Prevalence

Ottawa, Oct. 07, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global digital therapeutics market size reached USD 7.88 billion in 2024 and is estimated to attain USD 56.76 billion by 2034,...
September 16, 2025 13:00 ET | Source: UTR Therapeutics Inc.

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

UTR Therapeutics Inc Publishes Data supporting US FDA IND for a First-in-Human Clinical Trial of mRNA destabilizing drug targeting c-MYC driven cancer
September 04, 2025 11:00 ET | Source: Precedence Research

Monoclonal Antibodies Therapeutics Market Size Projected to Reach USD 1,057.91 Billion by 2034

Ottawa, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The global monoclonal antibody therapeutics market size was estimated at USD 265.17 billion in 2024 and is projected to reach approximately USD 1,057.91...
September 04, 2025 07:30 ET | Source: A Race Against Blindness

A Race Against Blindness Awards Additional $1 Million Grant to Advance Clinical Trial for Sight-Saving Gene Therapy for Bardet-Biedl Syndrome 1 (BBS1)

PHOENIX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, announced today that it has awarded...
September 03, 2025 09:00 ET | Source: Persephoni BioPartners

Persephoni Launches Strategic Sponsorship with American Cancer Society’s BrightEdge to Accelerate Oncology Innovation

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Persephoni BioSciences LLC ("Persephoni"), a leading global life sciences venture studio, is proud to announce a $1.5 million...